Renaissance Capital logo

Cortigent Filed Terms, Nasdaq: CRGT

Developing camera-based neural implants that restore partial vision to the blind.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

Cortigent, through its predecessor Second Sight Medical Products, Inc., is a pioneer in developing targeted neurostimulation systems to help patients recover critical body functions. Our technology combines advanced neuroscience with proprietary microelectronics, software, and data processing capabilities to provide artificial vision and potentially restore muscle movement. Our first commercial system, “Argus II,” was approved by the U.S. Food & Drug Administration (“FDA”) under a Humanitarian Device Exemption (“HDE”) and has provided artificial vision to hundreds of profoundly blind people who were implanted with this device. Building on this neurostimulation platform we have substantially completed an early feasibility clinical trial to evaluate a more advanced system for artificial vision that we call “Orion.” We are further exploring the application of our Orion® neurostimulation technology for accelerating the recovery of arm and hand function in patients who are partially paralyzed due to stroke. In February 2023, we held a meeting with the FDA to commence discussions of an early feasibility clinical study in stroke victims. We believe that additional future applications of our platform technology may have the potential to generate substantial business growth over time.
more less
IPO Data
IPO File Date 03/20/2023
Offer Price
Price Range $10.00 - $10.00
Offer Shares (mm) 1.5
Deal Size ($mm) $15
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $10.00 - $10.00
Offer Shares (mm) 1.5
Deal Size ($mm) $15
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
ThinkEquity
Company Data
Headquarters Valencia, CA, United States
Founded 1998
Employees at IPO 7
Website www.cortigent.com

Cortigent (CRGT) Performance